Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER) : a randomised, phase 3, non-inferiority trial
Copyright © 2019 Elsevier Ltd. All rights reserved..
BACKGROUND: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. In the FLYER trial, we assessed whether four cycles of CHOP plus six applications of rituximab are non-inferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with favourable prognosis.
METHODS: This two-arm, open-label, international, multicentre, prospective, randomised phase 3 non-inferiority trial was done at 138 clinical sites in Denmark, Israel, Italy, Norway, and Germany. We enrolled patients aged 18-60 years, with stage I-II disease, normal serum lactate dehydrogenase concentration, ECOG performance status 0-1, and without bulky disease (maximal tumour diameter <7·5 cm). Randomisation was computer-based and done centrally in a 1:1 ratio using the Pocock minimisation algorithm after stratification for centres, stage (I vs II), and extralymphatic sites (no vs yes). Patients were assigned to receive either six cycles of R-CHOP or four cycles of R-CHOP plus two doses of rituximab. CHOP comprised cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1·4 mg/m2, with a maximum total dose of 2 mg), all administered intravenously on day 1, plus oral prednisone or prednisolone at the discretion of the investigator (100 mg) administered on days 1-5. Rituximab was given at a dose of 375 mg/m2 of body surface area. Cycles were repeated every 21 days. No radiotherapy was planned except for testicular lymphoma treatment. The primary endpoint was progression-free survival after 3 years. The primary analysis was done in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of assigned treatment. A non-inferiority margin of -5·5% was chosen. The trial, which is completed, was prospectively registered at ClinicalTrials.gov, NCT00278421.
FINDINGS: Between Dec 2, 2005, and Oct 7, 2016, 592 patients were enrolled, of whom 295 patients were randomly assigned to receive six cycles of R-CHOP and 297 were assigned to receive four cycles of R-CHOP plus two doses of rituximab. Four patients in the four-cycles group withdrew informed consent before the start of treatment, so 588 patients were included in the intention-to-treat analysis. After a median follow-up of 66 months (IQR 42-100), 3-year progression-free survival of patients who had four cycles of R-CHOP plus two doses of rituximab was 96% (95% CI 94-99), which was 3% better (lower limit of the one-sided 95% CI for the difference was 0%) than six cycles of R-CHOP, demonstrating the non-inferiority of the four-cycles regimen. 294 haematological and 1036 non-haematological adverse events were documented in the four-cycles group compared with 426 haematological and 1280 non-haematological adverse events in the six-cycles group. Two patients, both in the six-cycles group, died during study therapy.
INTERPRETATION: In young patients with aggressive B-cell non-Hodgkin lymphoma and favourable prognosis, four cycles of R-CHOP is non-inferior to six cycles of R-CHOP, with relevant reduction of toxic effects. Thus, chemotherapy can be reduced without compromising outcomes in this population.
FUNDING: Deutsche Krebshilfe.
| Errataetall: |
CommentIn: Lancet. 2020 Dec 21;394(10216):2208-2209. - PMID 31868615 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:394 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 394(2019), 10216 vom: 21. Dez., Seite 2271-2281 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.01.2020 Date Revised 29.07.2020 published: Print ClinicalTrials.gov: NCT00278421 CommentIn: Lancet. 2020 Dec 21;394(10216):2208-2209. - PMID 31868615 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0140-6736(19)33008-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304690856 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304690856 | ||
| 003 | DE-627 | ||
| 005 | 20231225115526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(19)33008-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1015.xml |
| 035 | |a (DE-627)NLM304690856 | ||
| 035 | |a (NLM)31868632 | ||
| 035 | |a (PII)S0140-6736(19)33008-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Poeschel, Viola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER) |b a randomised, phase 3, non-inferiority trial |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2020 | ||
| 500 | |a Date Revised 29.07.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT00278421 | ||
| 500 | |a CommentIn: Lancet. 2020 Dec 21;394(10216):2208-2209. - PMID 31868615 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. In the FLYER trial, we assessed whether four cycles of CHOP plus six applications of rituximab are non-inferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with favourable prognosis | ||
| 520 | |a METHODS: This two-arm, open-label, international, multicentre, prospective, randomised phase 3 non-inferiority trial was done at 138 clinical sites in Denmark, Israel, Italy, Norway, and Germany. We enrolled patients aged 18-60 years, with stage I-II disease, normal serum lactate dehydrogenase concentration, ECOG performance status 0-1, and without bulky disease (maximal tumour diameter <7·5 cm). Randomisation was computer-based and done centrally in a 1:1 ratio using the Pocock minimisation algorithm after stratification for centres, stage (I vs II), and extralymphatic sites (no vs yes). Patients were assigned to receive either six cycles of R-CHOP or four cycles of R-CHOP plus two doses of rituximab. CHOP comprised cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1·4 mg/m2, with a maximum total dose of 2 mg), all administered intravenously on day 1, plus oral prednisone or prednisolone at the discretion of the investigator (100 mg) administered on days 1-5. Rituximab was given at a dose of 375 mg/m2 of body surface area. Cycles were repeated every 21 days. No radiotherapy was planned except for testicular lymphoma treatment. The primary endpoint was progression-free survival after 3 years. The primary analysis was done in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of assigned treatment. A non-inferiority margin of -5·5% was chosen. The trial, which is completed, was prospectively registered at ClinicalTrials.gov, NCT00278421 | ||
| 520 | |a FINDINGS: Between Dec 2, 2005, and Oct 7, 2016, 592 patients were enrolled, of whom 295 patients were randomly assigned to receive six cycles of R-CHOP and 297 were assigned to receive four cycles of R-CHOP plus two doses of rituximab. Four patients in the four-cycles group withdrew informed consent before the start of treatment, so 588 patients were included in the intention-to-treat analysis. After a median follow-up of 66 months (IQR 42-100), 3-year progression-free survival of patients who had four cycles of R-CHOP plus two doses of rituximab was 96% (95% CI 94-99), which was 3% better (lower limit of the one-sided 95% CI for the difference was 0%) than six cycles of R-CHOP, demonstrating the non-inferiority of the four-cycles regimen. 294 haematological and 1036 non-haematological adverse events were documented in the four-cycles group compared with 426 haematological and 1280 non-haematological adverse events in the six-cycles group. Two patients, both in the six-cycles group, died during study therapy | ||
| 520 | |a INTERPRETATION: In young patients with aggressive B-cell non-Hodgkin lymphoma and favourable prognosis, four cycles of R-CHOP is non-inferior to six cycles of R-CHOP, with relevant reduction of toxic effects. Thus, chemotherapy can be reduced without compromising outcomes in this population | ||
| 520 | |a FUNDING: Deutsche Krebshilfe | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Equivalence Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a R-CHOP protocol |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Vincristine |2 NLM | |
| 650 | 7 | |a 5J49Q6B70F |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Held, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Ziepert, Marita |e verfasserin |4 aut | |
| 700 | 1 | |a Witzens-Harig, Mathias |e verfasserin |4 aut | |
| 700 | 1 | |a Holte, Harald |e verfasserin |4 aut | |
| 700 | 1 | |a Thurner, Lorenz |e verfasserin |4 aut | |
| 700 | 1 | |a Borchmann, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Viardot, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Soekler, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Keller, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Truemper, Lorenz |e verfasserin |4 aut | |
| 700 | 1 | |a Mahlberg, Rolf |e verfasserin |4 aut | |
| 700 | 1 | |a Marks, Reinhard |e verfasserin |4 aut | |
| 700 | 1 | |a Hoeffkes, Heinz-Gert |e verfasserin |4 aut | |
| 700 | 1 | |a Metzner, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Dierlamm, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Frickhofen, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Haenel, Mathias |e verfasserin |4 aut | |
| 700 | 1 | |a Neubauer, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Kneba, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Merli, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Tucci, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a de Nully Brown, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Federico, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Lengfelder, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a di Rocco, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Trappe, Ralf |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenwald, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Berdel, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Maisenhoelder, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Shpilberg, Ofer |e verfasserin |4 aut | |
| 700 | 1 | |a Amam, Josif |e verfasserin |4 aut | |
| 700 | 1 | |a Christofyllakis, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Hartmann, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Murawski, Niels |e verfasserin |4 aut | |
| 700 | 1 | |a Stilgenbauer, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Nickelsen, Maike |e verfasserin |4 aut | |
| 700 | 1 | |a Wulf, Gerald |e verfasserin |4 aut | |
| 700 | 1 | |a Glass, Bertram |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitz, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Altmann, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Loeffler, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Pfreundschuh, Michael |e verfasserin |4 aut | |
| 700 | 0 | |a FLYER Trial Investigators |e verfasserin |4 aut | |
| 700 | 0 | |a German Lymphoma Alliance |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 394(2019), 10216 vom: 21. Dez., Seite 2271-2281 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:394 |g year:2019 |g number:10216 |g day:21 |g month:12 |g pages:2271-2281 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(19)33008-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 394 |j 2019 |e 10216 |b 21 |c 12 |h 2271-2281 | ||